US Trial Confirms Silver Diamine Fluoride Effectively Treats Severe Childhood Tooth Decay

Silver diamine fluoride (SDF) arrested between 50.2% and 57.5% of active cavitated dentin caries lesions in young children over an eight-month period, according to a phase 3 multisite clinical trial published in JAMA Pediatrics. The trial evaluated 830 generally healthy children aged 12 to 71 months with severe early childhood caries to inform US Food and Drug Administration (FDA) regulatory evaluation of the noninvasive treatment.

Clinical Trial Design and Patient Demographics

Researchers conducted a blinded, randomized, placebo-controlled trial across multiple sites, enrolling 830 participants aged 12 to 71 months who presented with severe early childhood caries, according to the study data. The trial randomized 414 children to receive 38% SDF and 416 children to receive a placebo. Eligible participants possessed at least one accessible, soft, cavitated dentin lesion suitable for SDF application. Children exhibiting caries-related pain, pulpal exposure, or active signs of infection were excluded from the study cohort.

Clinicians applied 38% SDF or a placebo at baseline and again at the six-month mark. The primary objective measured the efficacy of a single application in arresting cavitated dentin lesions at six months. Investigators subsequently assessed arresting efficacy at eight months, which marked two months following the second application. Intent-to-treat lesion-level analyses accounted for multiple lesions within individual patients and utilized multiple imputation to manage missing data.

Efficacy Rates and Comparison With Placebo Controls

The trial tracked 976 lesions in the SDF group and 1,011 lesions in the control group. Intent-to-treat analyses revealed that 38% SDF arrested an estimated 57.5% of lesions at three months, 54.0% at six months, and 50.2% at eight months, according to the published findings. Conversely, the placebo group demonstrated natural arrest rates of 18.8% at three months, 22.5% at six months, and 17.4% at eight months. These figures established statistically significant differences in arrest rates between the two groups, yielding gaps of 38.7 percentage points at three months, 31.5 percentage points at six months, and 32.8 percentage points at eight months.

The data showed that lesion arrest occurred rapidly within the first three months following the initial SDF application. However, a second application administered at six months produced no further statistically significant improvement in arrest rates at the eight-month assessment. Researchers noted that because the trial lacked a single-application comparison group at the eight-month mark, the study could not definitively establish whether the second application offered zero benefit. Exploratory analyses also uncovered higher arrest rates for lesions located on front teeth, which researchers attributed to easier access for routine dental hygiene.

Adverse Events and Safety Profiles

Adverse events occurred in 47.3% of participants in the SDF treatment group and 43.3% of participants in the control group, according to safety data from the trial. Treatment-related adverse events were reported at nearly identical rates: 22.9% for the SDF cohort and 22.2% for the placebo cohort. The vast majority of these incidents were classified as mild to moderate in severity.

Four participants assigned to the SDF group experienced severe adverse events, while zero severe events occurred in the placebo group. The study authors emphasized that the published paper does not state these severe events were directly caused by SDF administration. Furthermore, the trial observed no significant differences in pain levels between the SDF and control groups at either the six-month or eight-month follow-up intervals.

Public Health Implications for Underserved Communities

Severe early childhood caries affects nearly 50% of preschool children globally and 40% of children aged 2 to 19 in the United States, presenting a major public health challenge. Traditional management often requires repeated dental procedures performed under general anesthesia, which carries elevated financial costs, added medical risks, and potential neurological effects. SDF provides an affordable, noninvasive alternative that can be rapidly applied, making it particularly valuable for children living in underserved communities with restricted access to standard dental care.

Because roughly 20% of lesions in the control group met arrest criteria spontaneously and a substantial portion of lesions remained unarrested in the treatment arm, researchers advise that 38% SDF should supplement rather than replace comprehensive preventive dental strategies. Additional studies indicate that more frequent application schedules, such as monthly or four-month intervals, may achieve near-complete arrest of dentin caries in high-risk pediatric populations compared to six-month intervals.

Frequently Asked Questions

What is silver diamine fluoride (SDF)?

SDF is a noninvasive, liquid antimicrobial and remineralizing agent applied directly to teeth to arrest active dental caries and prevent further decay without drilling or local anesthesia.

Is 38% SDF FDA-approved for children?

While 38% SDF is FDA-cleared to treat adult dentin hypersensitivity, its use for arresting caries in pediatric patients remains off-label, though it holds an FDA Breakthrough Therapy designation.

Does SDF application cause pain for young children?

Clinical trial data show no significant difference in pain levels between children treated with SDF and those given a placebo during six- and eight-month follow-up periods.

Why might front teeth respond better to SDF treatment?

Exploratory analyses indicate that front teeth experience higher arrest rates primarily because dental anatomy allows for much easier access and better oral hygiene maintenance.